Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jan 6;12(1):161.
doi: 10.3390/nu12010161.

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

Ali Movahed  1 , Pema Raj  2   3   4 , Iraj Nabipour  1 , Marzieh Mahmoodi  1 , Afshin Ostovar  1 , Mohammadreza Kalantarhormozi  1 , Thomas Netticadan  2   3   4
Affiliations
Clinical Trial

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

Ali Movahed et al. Nutrients. .

Abstract

Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D.

Keywords: hemoglobin A1c; hyperglycemia; oxidative stress; resveratrol; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Consort flow diagram of the study.
Figure 2
Figure 2
(a–d) show the levels of Malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and total antioxidant capacity (TCA) at different time points, in patients with T1D. Data are presented as means ± SD. Signs (*) on the top of each time point are indicators of significant p values (p < 0.05) of pairwise comparisons. The comparisons between the two time points and their significant values were assessed by using the post hoc Bonferroni test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr. Diabetes Rep. 2013;13:795–804. doi: 10.1007/s11892-013-0433-5. - DOI - PubMed
    1. Maahs D.M., West N.A., Lawrence J.M., Mayer-Davis E.J. Epidemiology of type 1 diabetes. Endocrinol. Metab. Clin. N. Am. 2010;39:481–497. doi: 10.1016/j.ecl.2010.05.011. - DOI - PMC - PubMed
    1. Dandona P., Mathieu C., Phillip M., Hansen L., Tschöpe D., Thorén F., Xu J., Langkilde A.M. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018;41:2552–2559. doi: 10.2337/dc18-1087. - DOI - PubMed
    1. Miller K.M., Foster N.C., Beck R.W., Bergenstal R.M., DuBose S.N., DiMeglio L.A., Maahs D.M., Tamborlane W.V., Network T.D.E.C. Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971–978. doi: 10.2337/dc15-0078. - DOI - PubMed
    1. Seaquist E.R., Anderson J., Childs B., Cryer P., Dagogo-Jack S., Fish L., Heller S.R., Rodriguez H., Rosenzweig J., Vigersky R. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395. doi: 10.2337/dc12-2480. - DOI - PMC - PubMed

Publication types

MeSH terms